Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

App-Based study tracks quality of life in melanoma patients on targeted therapy

NCT ID NCT07022457

Knowledge-focused Sponsor: Pierre Fabre Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 50 adults in the UK with advanced BRAF V600 mutation-positive melanoma who are starting treatment with encorafenib and binimetinib. Instead of a controlled trial, it observes how these drugs work in real-world settings, focusing on patients' quality of life over 24 months. Participants use a smartphone app to report their well-being, while researchers also collect data from medical records.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
encorafenib and binimetinib (targeted therapy combination)
What this could lead to
If successful, this study could provide real-world evidence on how these drugs affect quality of life in everyday practice, helping doctors and patients make more informed treatment decisions.
What could go wrong
This is an observational study with only 50 participants, so results may not apply to everyone. It does not test new treatments or compare them to alternatives, so no major breakthroughs are expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients diagnosed with metastatic cutaneous BRAF V600 mutation-positive melanoma and assigned to receive encorafenib plus binimetinib as second-line treatment for metastatic melanoma, as per current Summary of Product Characteristics.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Aged 18 years or older * Willing and capable of providing written informed consent * Access to a smartphone * Diagnosis of metastatic cutaneous melanoma with presence of BRAF V600 mutation in tumour tissue prior to enrolment * Clinical decision has been made to begin encorafenib plus binimetinib treatment in accordance with current Summary of Product Characteristics * Encorafenib plus binimetinib to be prescribed as second-line treatment for BRAF V600-mutant metastatic melanoma Exclusion criteria: * Patients receiving systemic treatment for any tumours other than melanoma * Patients participating in a clinical trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic cutaneous melanoma with BRAF V600 mutation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cutaneous melanoma melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic melanoma, BRAF V600 mutation positive

Contacts and locations

Locations

  • Addenbrookes Hospital

    Cambridge, CB20QQ, United Kingdom

  • Queen Elizabeth Hospital

    Birmingham, B152GW, United Kingdom

  • Royal Marsden Hospital

    London, SW36JJ, United Kingdom

  • Royal Preston Hospital

    Preston, PR26GP, United Kingdom

  • Southampton General Hospital

    Southampton, SO166YD, United Kingdom

  • Southend University Hospital

    Westcliff-on-Sea, Essex, SS00RY, United Kingdom

  • University Hospital Coventry and Warwickshire

    Coventry, CV22DX, United Kingdom